Recruiting PHASE2 Brain Metastases, Adult

New treatment option for Brain Metastases, Adult

Official title RAPid SimPLE Targeted Radiation Treatment for Brain Metastases

ClinicalTrials.gov ID: NCT05050929

What this study is testing

What it's testing
The aim of the study is to show that rapid, simple targeted radiotherapy to brain metastases with 8 Gy / 1 is non-inferior to 20 Gy / 5 in terms of overall survival for patients with poor prognosis.
  • Phase 2: a mid-size study of how well it works
  • Which group you join is decided by chance.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 to 100

You may be able to join if

  • people must meet all of the following criteria to be eligible for participation in this study:
  • Age ≥ 18
  • Pathological diagnosis of a non-hematopoietic malignancy
  • Brain metastases of any size
  • Any number of untreated or progressing, previously treated brain metastases that can all be contoured and targeted

You likely can't join if

  • people are excluded from the study if any of the following criteria apply:
  • Inability to have a brain MRI
  • WBRT less than 3 months prior to randomization
  • Disseminated leptomeningeal carcinomatosis (limited pachymeningeal disease is permitted)
  • Multiple sclerosis
  • Neurologically declining despite corticosteroids
See the full eligibility criteria
Who can join
  • people must meet all of the following criteria to be eligible for participation in this study:
  • Age ≥ 18
  • Pathological diagnosis of a non-hematopoietic malignancy
  • Brain metastases of any size
  • Any number of untreated or progressing, previously treated brain metastases that can all be contoured and targeted
  • Presence of extracranial disease
  • Diagnosis-Specific Graded Prognostic Assessment ≤ 2.0. (https://brainmetgpa.com/) or Graded Prognostic Assessment ≤ 2.0 (Appendix I)
  • Able to complete the EuroQOL (EQ-5D-5L) questionnaire
  • Willing and able to have regular imaging follow up
  • Feasible to start protocol treatment within 14 days of participant enrolment
  • Karnofsky Performance Score (KPS) ≥ 50
What rules you out
  • people are excluded from the study if any of the following criteria apply:
  • Inability to have a brain MRI
  • WBRT less than 3 months prior to randomization
  • Disseminated leptomeningeal carcinomatosis (limited pachymeningeal disease is permitted)
  • Multiple sclerosis
  • Neurologically declining despite corticosteroids
  • Appropriate for surgery or stereotactic radiosurgery
  • Germ cell and primary brain tumours
  • Systemic lupus erythematosis, scleroderma, or other connective tissue disorders not in remission
  • Any other serious intercurrent illness or medical condition judged by the local investigator to compromise the participant's safety, preclude safe administration of the planned protocol treatment, or prevent the...
  • Pregnancy
  • Potentially fertile men or women of childbearing potential who are unwilling to employ highly effective contraception

The study team makes the final eligibility decision.

Where it's taking place

  • Abbotsford British Columbia, British Columbia, Canada
  • Kelowna, British Columbia, Canada
  • Prince George, British Columbia, Canada
  • Surrey, British Columbia, Canada
  • Vancouver, British Columbia, Canada
  • Victoria, British Columbia, Canada

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years to 100 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Abbotsford British Columbia, British Columbia, Canada; Kelowna, British Columbia, Canada; Prince George, British Columbia, Canada; Surrey, British Columbia, Canada; Vancouver, British Columbia, Canada; Victoria, British Columbia, Canada. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.